Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Operating Officer

CHIEF FINANCIAL OFFICER

Chief Financial Officer

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) dis...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-15	Premium	acquired	Premium	Premium	Premium	-
2024-03-15	Premium	sold	Premium	Premium	Premium	-
2024-03-14	Premium	acquired	Premium	Premium	Premium	-
2024-03-14	Premium	sold	Premium	Premium	Premium	-
2023-09-15	Premium	sold	Premium	Premium	Premium	-
2023-09-15	Premium	sold	Premium	Premium	Premium	-
2023-09-15	Premium	acquired	Premium	Premium	Premium	-
2023-01-03	Premium	acquired	Premium	Premium	Premium	-
2022-03-15	Premium	acquired	Premium	Premium	Premium	-
2021-11-19	Premium	bought	Premium	Premium	Premium	-
2021-11-18	Premium	bought	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2021-11-18	Premium	bought	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2021-11-18	Premium	bought	Premium	Premium	Premium	-
2021-11-17	Premium	bought	Premium	Premium	Premium	-
2021-11-17	Premium	bought	Premium	Premium	Premium	-
2021-05-12	Premium	bought	Premium	Premium	Premium	-
2020-08-19	Premium	gifted	Premium	Premium	Premium	-
2020-08-19	Premium	gifted	Premium	Premium	Premium	-
2020-01-10	Premium	acquired	Premium	Premium	Premium	-
2019-09-26	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2019-07-03	Premium	acquired	Premium	Premium	Premium	-
2019-06-26	Premium	bought	Premium	Premium	Premium	-
2019-06-25	Premium	bought	Premium	Premium	Premium	-

AXSM - Axsome Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for AXSM